May 27, 2010
Market overview: adult stem cell therapies
Even as regulatory agencies express abundant caution, adult stem cell therapies are moving steadily toward the clinic and through development for multiple applications. Investors have become more sophisticated about distinguishing between adult stem cell therapies and embryonic stem cell therapies as well as the potential risks, complications, and costs involved in each.
Source: Genetic Engineering News.
The following companies are mentioned: Osiris, TCA Cellular Therapy, Athersys, StemCells, Cytori Therapeutics, Celgene, Rodman & Renshaw, Genzyme, JCR Pharmaceuticals, Boston Scientific, Pfizer, Angiotech, GE Healthcare, Green Hospital Supply and Olympus.
UPDATE: “Game over for stem-cell clinic”, New Scientist.
